Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is epithelioid hemangioendothelioma?
Epithelioid hemangioendothelioma (EHE) is a rare cancer that arises from endothelial cells — the cells that line the inside of blood vessels. Because blood vessels run throughout the body, EHE can begin almost anywhere, but it most often appears in the liver, the lungs, the bones, and the soft tissues. A distinctive feature is that it frequently shows up as several spots at the same time within an organ — for example, multiple nodules scattered through the liver or both lungs — which can make it look like a cancer that has spread when in fact it is the way EHE typically presents. EHE is defined by a specific genetic change, most commonly a fusion of two genes called WWTR1 and CAMTA1, which can be confirmed on a biopsy and helps distinguish it from other vascular tumors. EHE is considered an 'intermediate' cancer: it is more serious than a benign growth but generally less aggressive than a high-grade sarcoma, and — unusually — its behavior varies enormously from person to person. In some people it stays stable for many years with no treatment at all, while in others it grows steadily or causes symptoms such as pain, and a smaller group have a more aggressive course. Because of this variability, there is no single treatment that fits everyone. Management is tailored to how the disease is behaving and may range from careful observation, to surgery for a single removable tumor, to systemic medicines for widespread or progressing disease — with radiation used to control specific tumors that are painful, growing, or threatening an important structure.
The main types
Doctors group epithelioid hemangioendothelioma by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Liver epithelioid hemangioendothelioma | One of the most common forms, usually appearing as multiple nodules throughout the liver; behavior ranges from stable for years to progressive, and for advanced liver disease a liver transplant is sometimes considered. |
| Lung epithelioid hemangioendothelioma | Often found as multiple small nodules in both lungs, sometimes discovered by chance; many remain stable, while others grow and cause breathlessness or cough and need treatment. |
| Bone epithelioid hemangioendothelioma | Can appear in one bone or several; it may cause pain or weaken the bone, and radiation is often used to control these tumors and relieve symptoms. |
| Soft-tissue epithelioid hemangioendothelioma | Arises in the soft tissues, sometimes connected to a blood vessel; a single tumor can often be removed surgically, sometimes with radiation to lower the chance of it returning. |
Staging, in plain terms
Epithelioid hemangioendothelioma is not staged with one tidy number, partly because it so often appears in multiple places at once and partly because its pace is so variable. Instead, doctors describe the disease by where it is, how widespread it is, and — most importantly — how it is behaving over time. A scan that shows several nodules in the liver or both lungs can be alarming, but in EHE this multifocal pattern is common at the outset and does not automatically mean the disease is rapidly progressing. The key questions are whether the spots are growing or stable on repeated imaging, whether they are causing symptoms such as pain or breathlessness, and whether certain higher-risk features are present — for example, larger liver tumors, the presence of fluid around the lung or in the abdomen, or significant pain — which studies link to a more aggressive course. Because behavior can only be judged over time, a period of close observation with repeat scans is sometimes the most informative first step, allowing the team to see whether the disease is the slow-moving kind that may need little intervention or the kind that is progressing and warrants active treatment. The practical questions that drive care are: how many sites are involved, is the disease growing, is it causing symptoms, and are there features that suggest a higher-risk course.
| No single standard stage number — care is guided by how many sites are involved, whether the disease is stable or progressing, the presence of symptoms, and certain risk features (such as the size of liver tumors and the presence of fluid or pain) | What it generally means |
|---|---|
| Single, removable tumor | Disease limited to one spot that can be taken out; surgery can be curative, sometimes with radiation to lower the chance of it returning. |
| Multifocal but stable | Several spots that are not growing and cause no symptoms; careful observation with repeat imaging is often appropriate, reserving treatment for if and when the disease changes. |
| Progressing or symptomatic | Disease that is growing or causing pain, breathlessness, or other problems; treated with systemic medicines, with surgery or focused radiation for specific problem tumors. |
| Advanced organ involvement | Extensive disease in an organ such as the liver; systemic therapy is used, and in selected cases of liver-confined disease a liver transplant may be considered. |
The standard of care
Epithelioid Hemangioendothelioma is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Active surveillance (watchful waiting)
Because EHE can stay stable for years, closely watching the disease with repeat scans is a legitimate and often-recommended first approach when it is not growing or causing symptoms, avoiding the side effects of unnecessary treatment.
Surgery for limited disease
When the cancer is confined to a single removable tumor, surgery can be curative; in advanced liver-only disease, a liver transplant is sometimes an option.
Radiation therapy
Used to control specific tumors that are painful, growing, or threatening an important structure — particularly in the bone — and after surgery in selected cases to lower the chance of recurrence.
Systemic therapy
For progressing or widespread disease, medicines including antiangiogenic drugs (which block blood-vessel growth), and in some cases other targeted agents, can slow or stabilize the cancer; clinical trials are an important option given the rarity of EHE.
Expert pathology with molecular testing
Confirming the diagnosis with the characteristic CAMTA1 marker and WWTR1-CAMTA1 gene fusion is essential, because EHE can be mistaken for other vascular tumors or for cancer that has spread from elsewhere.
Care at a sarcoma or rare-tumor center
Because EHE is rare and its management so individualized, treatment at a center experienced with vascular sarcomas gives the best chance of the right approach — including knowing when not to treat.
How radiation treatment works
Radiation therapy treats epithelioid hemangioendothelioma by delivering precisely aimed beams of energy that damage the DNA inside tumor cells so they can no longer grow and divide. Because EHE is an unusual cancer that often appears in several places at once and varies so much in pace, radiation is generally used in a targeted, problem-solving way rather than as a single treatment for the whole disease. Its most common role is local control of a specific tumor that is causing trouble — a deposit in a bone that is painful or threatening a fracture, a growing nodule pressing on an important structure, or a spot that is enlarging while the rest of the disease remains quiet. Focused radiation can shrink or stabilize such a tumor and relieve the symptoms it causes, often with a relatively short course. In the bone in particular, radiation is frequently the main local treatment because surgery there can be difficult. Radiation is also used after surgery in selected cases — when a single tumor has been removed but the margin is close — to sterilize any microscopic disease left at the edges and lower the chance of it returning. For a limited number of nodules in the lung, liver, or bone, stereotactic body radiation can deliver a concentrated, ablative dose to each spot while sparing surrounding tissue, an approach that fits EHE's tendency to grow slowly and appear in just a few sites. Importantly, because many people with EHE have disease that stays stable for years, radiation is reserved for tumors that genuinely need it; treating every spot regardless of behavior would add side effects without benefit. Throughout, modern planning shapes the dose tightly around each target so that nearby healthy organs — the liver, lungs, and bone marrow — are spared as much as possible.
The main ways radiation is delivered for epithelioid hemangioendothelioma:
Definitive radiation for bone tumors
Focused radiation controls EHE in the bone, relieving pain and reducing the risk of fracture, and is often the main local treatment when surgery isn't practical.
Postoperative (adjuvant) radiation
Radiation to the tumor bed after surgery sterilizes microscopic disease left behind, lowering the chance of recurrence when margins are close.
Stereotactic body radiation (SBRT)
Focused, high-dose beams can ablate a limited number of nodules in the lung, liver, or bone without surgery, providing durable control of isolated problem spots.
Palliative radiation
A short course of radiation can quickly relieve pain or other symptoms from a specific tumor, improving comfort and quality of life.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
Many EHE tumors can be safely observed: Studies show that a substantial number of people with epithelioid hemangioendothelioma have disease that remains stable for years, supporting active surveillance as a reasonable first approach when the cancer is not growing or causing symptoms.[1]
Natural-history and surveillance cohorts in EHE
Risk features predict a more aggressive course: Research has identified features — such as larger liver tumors, the presence of fluid around the lung or in the abdomen, and significant pain — that mark disease more likely to progress, helping teams decide who needs active treatment and who can be watched.[2]
Prognostic-stratification studies in EHE
Systemic and targeted options for progressing disease: For EHE that is growing, antiangiogenic and other targeted drugs can slow or stabilize the cancer, and ongoing trials — important given the disease's rarity — are testing agents aimed at the pathways driven by its characteristic gene fusion.[3]
Systemic-therapy and clinical-trial reports in advanced EHE
Common questions
My scan shows several tumors — does that mean my cancer has already spread? Not necessarily, and this is one of the most important things to understand about epithelioid hemangioendothelioma. Because EHE arises from the cells that line blood vessels, it commonly appears in multiple spots within an organ — such as several nodules through the liver or both lungs — right from the start. This multifocal pattern is the way the disease often shows up, not proof that it is rapidly spreading. What matters more is how those spots behave over time: whether they are stable or growing, and whether they are causing symptoms. That is why a period of close observation with repeat scans is sometimes the wisest first step, even when several tumors are present.
Why might my doctor recommend watching the cancer instead of treating it right away? Because EHE is unusual in how variable it is. In many people it stays stable for years and may never need active treatment, while in others it grows and does. Since the only reliable way to tell which course a person's disease will take is to watch it over time, careful surveillance with repeat imaging is often the most informative — and safest — first approach when the disease isn't growing or causing symptoms. This avoids the side effects of treatments that may not be needed. If the disease does begin to progress or cause problems, treatment can start then, targeting the specific tumors that need it.
When is radiation used for epithelioid hemangioendothelioma? Radiation in EHE is usually targeted at a specific tumor that is causing or threatening a problem rather than at the whole disease. The most common use is for a deposit in a bone that is painful or at risk of fracturing, where focused radiation controls the tumor and relieves pain. It is also used after surgery in selected cases to lower the chance of a removed tumor returning, and — for a small number of nodules in the lung, liver, or bone — stereotactic body radiation can deliver a concentrated, ablative dose to each spot. Because much EHE stays stable, radiation is reserved for tumors that genuinely need it rather than applied to every spot.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.